Abstract
Angiogenesis is defined as the physiological process by which new blood vessels develop from pre-existing vessels; either by sprouting or intussusception. Inhibition of angiogenesis is one of the most encouraging strategies to manage the growth and metastasis of cancers. The functional and proliferative status of blood vessels is regulated by the balance between various key molecules that either stimulate or inhibit angiogenesis. During quiescence, the “angiogenic switch” is “off”. However, during tumour development pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic and acidic fibroblast growth factor, tumour necrosis factor-α and interleukin-1 are pathologically enhanced. Persistent growth of tumour directed capillary networks creates a favourable microenvironment, promoting cancer growth, progression and metastasis. VEGF, particularly VEGF-A, is a key angiogenic factor. Targeting VEGF, its receptors and the downstream signaling cascade, is a viable strategy to prevent tumour growth and metastasis. The present review discusses the role of VEGF in tumour angiogenesis and the current understanding of anti-VEGF therapies as well as refractoriness of anti-angiogenesis cancer therapy.
Keywords: VEGF, tumour angiogenesis, angiogenic balance, anti-VEGF therapy, extracellular matrix, food and drug administration.
Current Vascular Pharmacology
Title:Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Volume: 15 Issue: 4
Author(s): Kodappully Sivaraman Siveen, Kirti Prabhu, Roopesh Krishnankutty, Shilpa Kuttikrishnan, Magdalini Tsakou, Feras Q. Alali, Said Dermime, Ramzi M. Mohammad and Shahab Uddin*
Affiliation:
- Translational Research Institute, Academic Health System, Hamad Medical Corporation, PO Box 3050, Doha,Qatar
Keywords: VEGF, tumour angiogenesis, angiogenic balance, anti-VEGF therapy, extracellular matrix, food and drug administration.
Abstract: Angiogenesis is defined as the physiological process by which new blood vessels develop from pre-existing vessels; either by sprouting or intussusception. Inhibition of angiogenesis is one of the most encouraging strategies to manage the growth and metastasis of cancers. The functional and proliferative status of blood vessels is regulated by the balance between various key molecules that either stimulate or inhibit angiogenesis. During quiescence, the “angiogenic switch” is “off”. However, during tumour development pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic and acidic fibroblast growth factor, tumour necrosis factor-α and interleukin-1 are pathologically enhanced. Persistent growth of tumour directed capillary networks creates a favourable microenvironment, promoting cancer growth, progression and metastasis. VEGF, particularly VEGF-A, is a key angiogenic factor. Targeting VEGF, its receptors and the downstream signaling cascade, is a viable strategy to prevent tumour growth and metastasis. The present review discusses the role of VEGF in tumour angiogenesis and the current understanding of anti-VEGF therapies as well as refractoriness of anti-angiogenesis cancer therapy.
Export Options
About this article
Cite this article as:
Siveen Sivaraman Kodappully , Prabhu Kirti , Krishnankutty Roopesh , Kuttikrishnan Shilpa , Tsakou Magdalini , Alali Q. Feras , Dermime Said , Mohammad M. Ramzi and Uddin Shahab *, Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges, Current Vascular Pharmacology 2017; 15 (4) . https://dx.doi.org/10.2174/1570161115666170105124038
DOI https://dx.doi.org/10.2174/1570161115666170105124038 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biosafety of Adenoviral Vectors
Current Gene Therapy (Section B: Integrated Function of Drug Transporters In Vivo) Drug Transport at the Blood-Brain Barrier and the Choroid Plexus
Current Drug Metabolism Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Modulation of Eosinophil Functions by Nitric Oxide: Cyclic GMPdependent and -independent Mechanisms
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Novel Approaches to the Therapy of Rheumatoid Arthritis based on an Understanding of Disease Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Molecular Imaging of Vascular Inflammation
Current Pharmaceutical Design Probing Cerebrovascular Alterations in Alzheimers Disease Using MRI: From Transgenic Models to Patients
Current Medical Imaging Systemic Vasculitis: An Epidemiological Perspective
Current Immunology Reviews (Discontinued) Impact of Macrophages in Atherosclerosis
Current Medicinal Chemistry Are Reactive Oxygen Species Important Mediators of Vascular Dysfunction?
Current Hypertension Reviews From a Dull Enzyme to Something Else: Facts and Perspectives Regarding Aldose Reductase
Current Medicinal Chemistry Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis
Current Medicinal Chemistry Henoch-Schönlein Purpura in Children: An Updated Review
Current Pediatric Reviews MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Transgenic Models in Allergic Responses
Current Drug Targets The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Current Rheumatology Reviews Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
Current Cancer Therapy Reviews